✦ LIBER ✦

Carboplatin/Etoposide/Paclitaxel in the Treatment of Patients with Extensive Small-Cell Lung Cancer

✍ Scribed by Harvey B. Niell; Michael C. Perry; Gerald Clamon; Jeffrey Crawford; Antonius A. Miller; James Herndon II; Mark R. Green

Book ID: 115076034
Publisher: CIG Media Group, LP.
Year: 2001
Tongue: English
Weight: 159 KB
Volume: 2
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2001.n.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Carboplatin and etoposide in extensive s

Carboplatin and etoposide in extensive small cell lung cancer

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Paclitaxel/epirubicin/etoposide in patie

Paclitaxel/epirubicin/etoposide in patients with extensive-disease small-cell lung cancer (SCLC)

✍ Baldini, E.; Chella, A.; Del Freo, A.; Gragnani, F.; Angeletti, C.A.; Conte, P.F 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 332 KB

Paclitaxel, carboplatin, and extended sc

Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung cancer

✍ Hainsworth, John D.; Greco, F.Anthony 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Determining carboplatin/etoposide dosage

Determining carboplatin/etoposide dosage in extensive stage small-cell lung cancer (SCLC)

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Phase III study of cyclophosphamide, dox

Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer

✍ Wouter K. de Jong; Harry J.M. Groen; Mia G.J. Koolen; Bonne Biesma; Luuk N.A. Wi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Paclitaxel, carboplatin, and extended sc

Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma

✍ John D. Hainsworth; Steven L. Stroup; F. Anthony Greco 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 577 KB

## BACKGROUND. Paclitaxel is an active agent in the initial treatment of patients with small cell lung carcinoma. The authors evaluated the toxicity and efficacy of paclitaxel (1-hour infusion) added to a standard combination regimen of carboplatin and etoposide in a Phase I1 trial for the treatme